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6 a CR phenotype have been directly isolated from the metastasis of PCa to the bones and brains of patients, such as PC-3 and DU-145, respectively (6, 7) .
QRT-PCR of the (mitochondrial encoded) ND1 in the denoted cell lines revealed that the copy number of the mitochondrial genome content is elevated in the early stage PCa (LNCaP) in comparison to the normal prostate epithelial cells (PrEC) (see Figure 2 in appendix). The copy number of the mitochondrial genome was lower in CR PCa (C4-2, PC-3 and DU-145) in comparison to LNCaP (see Figure 1B in Cook et al., attached document) (8) . It is important to note that the mitochondrial genome content was significantly reduced in the in vivo progression of LNCaP to C4-2 (see Figure  1B in Cook et al.) . The analysis of the mitochondrial genomic content in the classical PCa cell lines revealed that the shift of normal prostate epithelial cells to the early stages of PCa transiently amplifies the copy number of the mitochondrial genome. Subsequentially, the copy number is depleted as the disease progresses to CR. The transient amplification and, subsequent, depletion in the copy-number of the mitochondrial genome can be an explanation for the Warburg Effect that is a classical phenomenon observed in the development of cancers (9) .
Warburg Effect: the development of cancer is associated with a genomic insult to cellular ('mitochondrial') respiration, in addition to a flux in fermentation as the disease progresses to an advanced phenotype (9) .
II. Characterization of the mitochondrial genome content within cell lines which model the depletion of the mitochondrial genome in the progression of cancers (PCa and BCa) to advanced diseases. The identification of the mitochondrial genome as a biomarker in the progression of PCa warranted the creation of cell models for the depletion of the mitochondrial genome content in the progression of PCa to a disease that is CR. Human cancers are not viable if mitochondria as a whole are removed. Mitochondria serve multiple roles for the eukaryote including ATP synthesis, redox regulation, thermogenesis, calcium regulation, and production of secondary messengers that are essential for cellular differentiation and the cell cycle (10) . It is possible to generate viable cancers that are depleted of the mitochondrial genome, which are denoted as ρ0. In the process of constructing a ρ0 from a parental cell line, there is a potential that mutation(s) can incidentally be introduced into the nuclear genome of the ρ0. The incidental mutation(s) would generate a genomic background in the ρ0 that differs in comparison to the parental cell line (11) . To address the potential for incidental mutations in the creation process of ρ0, proper controls were established with the fusion of ρ0 to cytoplast that can be derived from the parental cell line, platelets, or synaptosomes. The fusion product is the formation of a cybrid cell line that retains the nuclear-genome from the parental cell, yet harbors a mitochondrial genome content that was donated from the cytoplast (12, 13) . Since the cytoplast contain no nucleus and no nuclear genome, if a phenotype generated with the depletion of the mitochondrial genome from cancer is attenuated with the reconstitution of the mitochondrial genome, the shared nuclear background of the ρ0 and cybrid allows for the phenotype to be specifically attributed to the depletion of the mitochondrial genome. In other words the ρ0 and cybrid confirm the phenotype is not a result of incidental nuclear mutation created in the knock out process. To this end, the following experiments were conducted to visually and quantitatively confirm the knock-out and knock-in of the mitochondrial genome content within ρ0 and cybrid created from parental PCa (LNCaP) and breast cancer (BCa) (MCF-7).
PCa and BCa share similar epidemiology as the second leading causes of cancer mortality in men and women in the US (14) . The cancers are the leading cancers diagnosed in the respective sexes, when basal and squamous cell skin cancers are excluded. Moreover, PCa and BCa share similar phenotypic characteristics during the progression of the cancers. The cancers originate as tumors that rely on androgen and/or endocrine sensitive signals to maintain viability, however with time the tumors can dedifferentiate into CR phenotypes that are no longer confined to hormone signals. MCF-7 is a classic human BCa cell line that is castration-sensitive, established from the metastasis (pleural effusion) of breast adenocarcinoma (15) .
The ρ0 of MCF-7 and LNCaP have been previously constructed and denoted as MCFρ0 and LNρ0-8, in addition to characterized as CR (16, 17) . Briefly, the mitochondrial genome content was depleted from the parental cell lines by the addition of ethidium-bromide to the culture of cells. It is presumed that ethidium-bromide depletes the mitochondrial genome, preferentially over the mutation of the nuclear genome, due to the unique complementation in the charges of ethidium-bromide and mitochondria. To refine the phenotypic and molecular analysis that can be conducted with ρ0, cybrid controls were constructed from the fusion of platelets to LNρ0-8 and MCFρ0 cells, and denoted as LNCyb and MCFCyb.
In Annual Year II, the mitochondrial genomic contents of the classic cell lines and the experimental (mtDNA-KO and mtDNA-KI) cell lines were confirmed with fluorescent in situ hybridization (FISH). Briefly, mitochondria were labeled with MitoTracker Red prior to fixation. Fixed cells were subjected to FISH with Alexa-488 labeled oligos (~ 600 bp) that collectively represent the entire sequence of the mitochondrial genome. Confocal microscopic images confirmed an abundance of the mtDNA probes were localized within the mitochondria of LNCaP and MCF-7, in addition to, the corresponding cybrids. No mtDNA probes were observed in the ρ0 (see Figure 1C in Cook et al., attached document). The microscopic results were supported with the quantification of the mitochondrial genome content of single cells with QRT-PCR that was reported in Annual Year I (see Figure 1D in Cook et al.) . The copy numbers obtained for the ρ0 were 8 elevated protein levels of K-Ras 4A in comparison to the parental and cybrid (see Figure 3A in Cook et al.) . The evidence reveals that the depletion of the mitochondrial genome in PCa and BCa enhances the expression of K-Ras 4A, and that the aberrant expression of K-Ras 4A can be attenuated with the reconstitution of the mitochondrial genome. Further analysis of the expression of K-Ras 4A in lysates collected from CR PCa (C4-2, PC-3, DU-145, and LNρ0-8) revealed that the cellular expression of K-Ras 4A was inversely associated with the copy number of the mitochondrial genome (see Figure 3C in Cook et al.) .
In a subsequent experiment, the relative levels of the transcripts for the Ras isoforms in LNCaP and MCF-7, in comparison to, corresponding ρ0 and cybrid models, were evaluated with reverse-transcription (RT) PCR of total-RNA lysates collected from the denoted cell lines. RT-PCR revealed that the depletion of the mitochondrial genome elevated the cellular transcript levels of K-Ras 4A. Moreover, the amplified transcript levels were attenuated with the reconstitution of the mitochondrial genome to the ρ0 in the construction of cybrids (see Figure 3B in Cook et al.). The observations suggest that a reduction in the copy number of the mitochondrial genome generates a flux in a Ras-to-ERK and Ras-to-Akt signal through an elevation in the transcription and activation of Ras-GPTases, predominantly K-Ras 4A.
IV. 'Proto-oncogenic' Ras is aberrantly activated when the copy number of the mitochondrial genome content is reduced in PCa and BCa. K-RAS is converted from a proto-oncogene to an oncogene in the development of a variety of cancers, such as colon cancer. Oncogenic Ras is often characterized with point mutations in codons that encode the P loop (P-L) or Switch-II (SW-II) region of the GTPase. The oncogenic mutations, ultimately, generate an intracellular accumulation of GTP-bound Ras (34) . Mutations in exon one (codon 12 or 13) can encode amino-acid substitutions that render the P-L region insensitive to the activity of Ras-GTPase Activating Proteins (RasGAPs). RasGAPs catalyze the intrinsic GTPase domain of Ras and, thus, the dynamic deactivation of the molecule. The GTPase activity of Ras can be directly diminished with mutations of codon 61 in exon two. Oncogenic mutations in codon 61 encode amino-acid substitutions in the SW-II region (35) .
In Annual Year II an evaluation of the genomic sequence of K-RAS from total-DNA lysates collected from the ρ0 of LNCaP and MCF-7 revealed codons 12, 13, and 61 of the gene to be void of oncogenic mutations (data not shown). Moreover, the characterization of K-RAS as proto-oncogenic was supported with the transfection of K-RAS siRNA into LNρ0-8. The transfection showed that the reduction of the cellular expression of K-Ras attenuated the aberrant phosphorylation of ERK and Akt (see Figure 3D in Cook et al., attached document). The evidence strongly suggests that the constitutive activation of K-Ras, generated with the depletion of the mitochondrial genome content in PCa and BCa, is likely of a metabolic origin rather than derived from an oncogenic mutation.
It is important to note that normal prostate epithelial cells (PrEC) harbored a low copy number of the mitochondrial genome in comparison to early stage PCa (LNCaP), yet the cellular expression of GTP-bound Ras was not amplified in PrEC as was observed in CR PCa, which were characterized with low copy numbers of the mitochondrial genome (C4-2, PC-3, DU145, and LρN0-8) (see Figure 2 and 3 in appendix). Regarding this paradox, reports have shown that the RasGAP activity of the DOC-2/DAB2 interactive protein (DAB2IP) is silenced in the transformation of prostate epithelial cells to PCa, predisposing the cancers to an accumulation of GTP-bound Ras (36) (37) (38) . Western blot of DAB2IP in total-protein lysates collected from normal prostate epithelial cells (PrEC), early-stage PCa (LNCaP), and CR PCa (C4-2, PC-3, DU-145, and LNρ0-8) revealed that the cellular expression of DAB2IP was diminished in early stage PCa and CR PCa, in comparison to normal prostate epithelial cells (see Figure 2C in Cook et al.) . Based on the observation that early stage PCa maintains the ability to dynamically modulate the Ras pathway (see Figure 2A and 2B in Cook et al.), the silencing of DAB2IP, alone, cannot explain the constitutive activation of Ras that was observed in CR PCa. It is warranted to postulate that the silencing of DAB2IP in the transformation of normal prostate epithelial cells to PCa predisposes the disease to an accumulation of GTP-bound Ras that are generated downstream to a reduction in the mitochondrial genome content.
V. The reduction-to-depletion of the mitochondrial genome content in PCa induces the mevalonate pathway to activate Ras effectors (ERK and Akt).
Ras is void of a transmembrane domain. Post-translational modifications are required to enable GTP-bound Ras-Raf complexes to activate Ras effectors at the cellular membrane (39) . An addition of farnesyl to the first cysteine in the C-terminus (CAAX) of Ras, i.e., prenylation, can enable the localization of Ras to the cellular membrane (40) . The farnesyl moieties are derived from an intermediate of the mevalonate pathway, farnesyl pyrophosphate. Farnesyltransferase (FTase) catalytically transfers farnesyl moieties to Ras (41) .
The farnesylation of Ras can be repressed with lovastatin-mediated inhibition of the HMG-CoA reductase (HMGR) enzyme, or, in other words, the metabolism of HMG-CoA to mevalonate (42) . HMGR is a rate-limiting enzyme of the mevalonate pathway (43) . To directly inhibit the farnesylation of Ras, farnesyltransferase inhibitors (FTIs) have been designed as peptidomimetics of the C-terminus of Ras (CAAX) (44) . Specific FTIs, such as FTI-276, have been created to be selective for FTase over geranylgeranyl transferase I that is responsible for the posttranslational lipidation of CAAX proteins such as RHOA, RAC1, and CDC42 (44, 45) .
In Annual Year II, confocal (z-slice) images and anti-Ras were used to probe fixed samples of early stage PCa (LNCaP), and, corresponding ρ0 and cybrid (see Figure 4A in Cook et al., attached document). Ras was primarily observed to be in the cytosol of early stage PCa. Localization of Ras shifted to the cellular membrane after depletion of the mitochondrial genome content. The aberrant localization of Ras was inhibited after the addition of lovastatin to the culture of ρ0. It is important to note that the lovastatin-mediated effect on Ras was inhibited with the co-application of exogenous mevalonate (see Figure 4B in Cook et al.). Moreover, a corresponding western blot of total-protein lysates collected from LNρ0-8 cultured in the presence of lovastatin or FTI-276 revealed either agent could diminish the aberrant phosphorylation of Ras effectors (ERK and Akt) that were previously demonstrated to be downstream of the depletion of the mitochondrial genome content (see Figure 4C and Figure 4D in Cook et al.). The results support the postulate that a reduction in the copy number of the mitochondrial genome content generates a flux in the mevalonate pathway that induces the aberrant activation of Ras, in addition to, ERK and Akt.
The human cell regulates the activity of the mevalonate pathway with multiple feedback mechanisms to HMGR, including transcriptional and/or translational regulation, PTMs, and/or proteasomal degradation by both sterol and non-sterol products of the mevalonate pathway (46, 47) . A western blot was used to evaluate the protein levels of HMGR in total-protein lysates collected from normal prostate epithelial cells (PrEC), early-stage PCa (LNCaP), and CR PCa (C4-2, PC-3, DU-145, and LNρ0-8). The cellular expression of HMGR was inversely associated with the copy number of the mitochondrial genome content (see Figure 4F in Cook et al.). Moreover, a western blot of total-protein lysates collected from LNCaP, and, corresponding ρ0 and cybrid models confirmed that the depletion of the mitochondria genome content elevates the cellular expression of HMGR. The phenomenon was noted to attenuate with the reconstitution of the mitochondrial genomic content (see Figure 4E in Cook et al.).
Interestingly, western blot of HMGR in total-protein lysates collected from LNCaP cultured in the presence of proteasomal inhibitor (ALLN) revealed that the ALLN increased the protein level of HMGR (see Figure 5B in Cook et al.). It is important to note that RT-PCR of the relative transcript level of HMGR in early stage PCa (LNCaP) and early stage BCa (MCF-7), in comparison to, corresponding ρ0 and cybrid suggest that the depletion of the mitochondrial genome content does not alter the cellular transcript levels of HMGR (data not shown). It is warranted to speculate that proteasomal degradation dampens the cellular expression of HMGR in the early stages of PCa, until a reduction in the mitochondrial genome content diminishes the proteosomal degradation of HMGR, subsequentially generating a flux in the mevalonate pathway that activates Ras signals to ERK and Akt.
VI. The cellular expression of HMGR and phosphorylation of ERK are amplified with the reduction-to-depletion of the mitochondrial genome content in PCa, in response to a normoxic-to-hyperoxic shift that is generated with the dysfunction of mitochondrial respiration. Recent reports have demonstrated that the exposure of cells to hypoxic conditions induces proteasomal degradation of the HMGR expressed within cells (48, 49) . In Annual Year II, the level of hypoxia within cells was indirectly measured with quantification of the oxygen gas (O 2 ) concentration at the bottom of a 96 well OxoPlate. The O 2 concentration in cell-free media that was saturated with air was 217 µM. An inclusion of early stage PCa (LNCaP) to the OxoPlate media generated a normoxic-to-hypoxic shift that was significant in comparison to CR PCa (C4-2, PC-3, DU-145, and LNρ0-8) (see Figure 6G An analysis of normal prostate epithelial cells (PrEC) in the OxoPlate revealed that the cells have a strong hypoxicinducing ability in comparison to early stage PCa (LNCaP) (see Figure 4 in appendix), which were previously denoted to harbor a higher copy number in the mitochondrial genome content (see Figure 2 in appendix). The observation warrants the postulate that the decrease in the hypoxic-inducing ability of PCa, in comparison to normal prostate epithelial cells, is a consequence of the diminished MRC activity that is generated from a mitochondrial genome content that is amplified or diminished but, yet, damaged in the process of carcinogenesis. Moreover, it is hypothesized that the hypoxic-inducing ability of prostate epithelial cells enables the cells to dynamically inactive the Ras-to ERK and Akt signals that are constitutively and progressively activated as the mitochondrial genomic content is depleted in the progression of the disease to the CR phenotype.
As a means to evaluate if hypoxic-to-normoxic shifts generate the constitutive activation of the Ras pathway, hyperoxia was exogenously established in OxoPlate cultures of early stage PCa (LNCaP) with the incubation of cells in an enriched O 2 environment. The protein level of HMGR and the phosphorylation level of ERK were evaluated with western blot of total-protein lysates collected from LNCaP cultured in an atmosphere of normoxia or hyperoxia (20 % O 2 , 217 µM or 30 % O 2 , 310 µM). The protein level of HMGR and phosphorylated ERK were increased within 6 hours of incubation of LNCaP in a hyperoxic chamber (see Figure 6D in Cook et al.).
As an alternative technique to confirm that a hypoxic-to-normoxic shift aberrantly activates the Ras, the protein level of HMGR and the phosphorylation of ERK were evaluated with western blot of total-protein lysates collected from LNρ0-8 cultured in an atmosphere of normoxia (control) or hypoxia. Hypoxia was defined as 0.2% O 2 , 2.1 µM, and used to induce a hyperoxic-to-normoxic shift in the ρ0. The results demonstrate that the culture of LNρ0-8 in a hypoxic culture for 6 hours diminished the protein level of HMGR and the phosphorylation of ERK (see Figure 6E and Figure 6F in Cook et al.). The experimental induction of the hyperoxic-to-normoxic shift in the ρ0 mirrors the evidence generated from the experimental induction of the normoxic-to-hyperoxic shift in the parental LNCaP (see Figure 6D in Cook et al.). The collective evidence supports the postulate that the cellular O 2 concentration is a physical link downstream of the reduction-to-depletion of the mitochondrial genome content that generates an aberrant activation of the mevalonate-to-Ras pathway. We denote the coherent series of events as the mitoGPS for the progression of PCa and BCa cancers to advanced diseases. It is important to note that the mitoGPS could be reversed with the reconstitution of a (donor) mitochondrial genome to ρ0.
AIM TWO: Investigation of the biological impact of a constitutive ERK1/2 signal on the progression of anti-androgen resistance in human PCa cell lines reduced or depleted in mtDNA.
VII. The CR phenotype is generated in response to a flux in the mitoGPS, after the depletion of the mitochondrial genome content in PCa. Over half a century ago, the Nobel laurite Charles Huggins reported that the viability of primary and metastatic PCa tumors was sensitive to the pharmacological inhibition of the hypothalamo-pituitary-gonadal axis. In other words, Huggins discovered that PCa was sensitive to the ablation of the systemic circulation of androgens (50) . To this date, the pharmaceutical inhibition or anatomical inhibition of the axis has become a mainstay treatment for invasive PCa. While the tumors of patients with invasive and metastatic PCa recede with ADT, unfortunately, the majority of patients develop secondary CR tumors that are resistant to ADT (51) . A similar phenomenon of resistance is often reported after the treatment of invasive and metastatic PCa with anti-androgens, such as flutamide. Flutamide is a competitive inhibitor to testosterone and dihydrotestosterone for the binding of the AR. In the treatment of invasive and metastatic PCa, the exposure to antiandrogens causes the disease to initially recede, and then the disease progress to an AAR phenotype that is inevitably fatal (14) . Even though PCa can be effectively treated in the early stages, the potential for PCa to differentiate makes the disease the most deadly cancer for American men. In 2009 an estimated 27,360 men died as a consequence of an incomplete understanding of the cellular mechanisms of CR. The ability for PCa to remain viable outside the confined structure of the prostate, in addition to, the presence of blockades of the androgen to androgen-receptor, warrants the postulate that the mitoGPS generates the CR phenotype.
LNCaP is a classic cell line that represents the androgen sensitive phenotype of early stage PCa. In Annual Year I, an androgen dependence and sensitivity assay was used to confirm the androgen dependence of LNCaP. The culture media in the assay was charcoal stripped of androgens. Briefly, LNCaP was seeded at a concentration of 2,000 cells/well, overnight. The cells were cultured 7 days in charcoal stripped media supplemented with synthetic androgen R1881 and/or exogenous mevalonate. As a control, cells were also cultured in charcoal stripped media with no supplementation. Posttreatment, the viability of cell cultures was evaluated with the quantification of cellular proliferation from a calcein assay (see Figure 7E in Cook et al., attached document). Cell viability was also visually assessed with wide field (phase-contrast) microscopy (see Figure 7A -7D in Cook et al.). The results of the calcein assay and microscopic images demonstrate that the viability of early stage PCa (LNCaP) was enhanced when cultured in the presence of exogenous androgen. The cotreatment of mevalonate attenuated the dose-dependent effect that androgen elicited on the viability of LNCaP. Moreover, exogenous mevalonate supported the viability of LNCaP in the absence of exogenous androgen. The results demonstrate that the viability of early stage PCa can be supported by the androgen signal and/or a flux in the mevalonate pathway.
It has been previously reported that a reduction-to-depletion in the mitochondrial genomic contents of PCa progress the disease to the CR phenotype (8, 16, 52, 53) . To access if the phenomenon is generated from a flux in the mitoGPS, the ρ0 of LNCaP (LNρ0-8) was cultured 48 hr in the absence (control) or presence of lovastatin. The cell cultures were additionally supplemented without or with mevalonate. Post-treatment, the viability of cell cultures was assessed with the quantification of cellular proliferation from a crystal violet assay. Lovastatin lowered the viability of LNρ0-8. Moreover, the effect of lovastatin was attenuated with the co-application of mevalonate, which induced a flux in the mevalonate pathway in the face of the lovastatin-induced blockade of HMGR (see Figure 7G VIII. Fluxes in the mevalonate pathway enhance the viability of early stage PCa (LNCaP) in mouse (xenograft) models. Early stage PCa (LNCaP) is known to gradually acquire more aggressive growth, in vitro and in vivo (289, 290). To investigate if cellular fluxes in the mevalonate pathway enhance the growth of PCa tumor, in Annual Year II, LNCaP were inoculated into athymic nude mice to evaluate the in vivo effect of the application (injection) of mevalonate and/or consumption of lovastatin. The natural increase in the in vivo growth of LNCaP tumors was observed over time (see Figure  8A in Cook et al., attached document). Lovastatin attenuated the progressive growth of the tumors, while a co-treatment with mevalonate inhibited the lovastatin-mediated effects. The treatment of mevalonate, alone, showed a slight but significant ability to enhance tumor growth (see Figure 8E in Cook et al.). The results indicate that a flux in the mevalonate pathway can enhance the in vivo growth of early stage PCa (LNCaP), potentially due to a silencing of RasGAPs in the transformation of prostate epithelial cells to PCa, which predisposes the cancer to autonomous growth generated from GTP-bound Ras.
IX: The expression of AR is diminished in response to a flux in the mitoGPS that is generated after the depletion of the mitochondrial genome content in PCa. Reports have estimated that 20-30% of the cell population in an advanced PCa tumor is characterized with an extensive loss in the cellular expression of AR (54) . The AR-negative cells are biologically significant. Chin et al. demonstrated that AR-negative cells generate metastasis-related factors that promote the osteoblastic progression of PCa (55) . In respect to the progression of BCa to the CR phenotype, Tseng et al. has shown that mitochondrial genomic mutations in the non-coding (D)-loop are associated with the silenced expression of the estrogen receptor and progesterone receptor in advanced BCa cell lines (53) .
As a means to evaluate if the copy number of the mitochondrial genome was inversely associated with the cellular expression of AR in PCa, in Annual Year I total-protein lysates of LNCaP and the corresponding ρ0 were probed with anti-AR in a western blot. The cellular expression of AR was diminished in LNρ0-8 in comparison to the parental LNCaP (see Figure  5 in appendix). This result warrants the postulate that the mevalonate-to-Ras component of the mitoGPS diminishes the cellular expression of the AR in PCa that is depleted of mitochondrial genomic content. In a corresponding experiment, the cellular expression of AR was quantified for LNρ0-8 that was cultured 48 hr in the absence or under the pharmaceutical inhibition of ERK. PD98059 is a non-competitive inhibitor of MEK, the upstream activator of ERK in the Ras pathway. Totalprotein lysates collected from the denoted cultures were subjected to SDS-PAGE and probed with anti-AR in a western blot. Total-protein lysates of LNCaP were evaluated as a positive control for the AR. Total-protein lysates were additionally probed with anti-phospho ERK to confirm that PD98059-induced the inhibition of ERK. The addition of PD98059 to the culture of ρ0 attenuated the phosphorylation of ERK and elevated the expression of AR (see Figure 5 in appendix). Similar results were observed when LNρ0-8 was cultured 48 hr in presence of GW5074 or U0126 (see Figure 6 in appendix). U0126 is a noncompetitive inhibitor of MEK. GW5074 is a competitive inhibitor of raf-1, the upstream activator of MEK in the Ras pathway. The evidence suggests that a flux in the mitoGPS, as a response to a reduction-to-depletion in the copy number of the mitochondrial genomic content in PCa, can diminish the cellular expression of AR. Preliminary results suggest that the mitoGPS, in part, regulates the cellular expression of AR at the transcript level (see Figure 7 in appendix). X: The AAR phenotype is generated in response to a flux in the mitoGPS that is generated after the depletion of the mitochondrial genome content in PCa. LNCaP is a classic cell line that models the anti-androgen sensitivity of early stage PCa. In Annual Year I the sensitivity of LNCaP to anti-androgen was confirmed with an anti-androgen sensitivity assay (see Figure 4H ). Briefly, LNCaP was seeded at 2,000 cells/well in a 96 well plate, overnight. Cells were cultured 4 days in the absence or presence of the anti-androgen, flutamide. The viability of the cell cultures was assessed with the quantification of cellular proliferation from a calcein assay. The results demonstrate that the viability of LNCaP was decreased in the presence of flutamide and, thus, anti-androgen sensitive (see Figure 8 in appendix).
Previously it was noted from western blot that the cellular expression of AR was diminished in the ρ0 of early stage PCa (LNCaP) (see Figure 5 and 6 in appendix). Moreover, the application of PD98059, GW5074, or U0126 to cultures of LNρ0-8 could regenerate the expression of AR that was silenced with depletion of the mitochondria genome content from the parental LNCaP (see Figure 5 and 6 in appendix). In a corresponding experiment the viability of LNρ0-8 was evaluated with an anti-androgen assay to assess if the AAR phenotype concurrently develops with the silencing of the AR in ρ0. The results revealed that the cellular proliferation of LNρ0-8 was not significantly decreased from the exposure of the ρ0 to a concentration of flutamide that diminished the viability of the parental LNCaP (see Figure 9 in appendix). In a corresponding experiment the AAR phenotype of LNρ0-8 was assessed with an anti-androgen sensitive assay after 4 days of culture of the ρ0 in media that was additionally supplemented without (control) or with 40 µM PD98059. The anti-androgen sensitivity assay confirmed PD98059 attenuated the AAR phenotype of LNρ0-8 (see Figure 9 in appendix). The comparison of the AR expression and the anti-androgen sensitive assays of LNCaP, in addition to corresponding ρ0 and cybrid, confirm that PCa progress to an AAR phenotype in response to a depletion of the mitochondrial genome content. Experimentation with inhibitors of the Ras-to-ERK pathway demonstrate that the advanced (CR and AAR) phenotype can be derived from the constitutive activation of a mitoGPS that is activated in response to depletion of the mitochondrial genome content in PCa.
Key Research Accomplishments:
• The characterization of mitochondrial DNA contents of single cancer cells from human PCa tumors, of a low grade and a high grade, indicated that cancer cells from high grade tumors had a low mitochondrial genome content in comparison to low grade tumors. • The characterization of mitochondrial DNA contents of single cancer cells from classical PCa cell lines revealed a low mitochondrial genome content in CR PCa in comparison early stage PCa.
• Experimental models for the depletion of the mitochondrial genome content (i.e., ρ0) were created with the knockout of the mitochondrial genome from early stage PCa (LNCaP) and early stage (BCA). A knock-in of the mitochondrial genome was generated from the fusion of platelets (donor mitochondria) with ρ0 in the creation of cybrids.
• From the classical cell lines and experimental cell models was discovered the components of a mitochondrialretrograde signal that progresses PCa to the CR phenotype, in response to a reduction-to-depletion of the mitochondrial genome. Briefly, as the copy number of the mitochondrial genome is reduced the, subsequent, dysfunction of the MRC was found to induce a flux in the cellular O 2 concentration that shifted cells from a hypoxic-to-normoxic state. The hypoxic-to-normoxic shift was found to be transduced into the metabolic profile of a cancer cell, at the level of the cellular expression of the rate limiting enzyme of the mevalonate pathway, HMGR. Ultimately, the reduction-to-depletion of the mitochondrial genome content was found to induce a flux in the mevalonate (HMGR) pathway, which generated the constitutive activation of proto-oncogenic Ras (predominantly, K-Ras 4A) and a diverse array of effectors of Ras, such as ERK and Akt.
Research Outcomes:
• The core results from the project were peer reviewed and published. 
Conclusions:
The discovery of the mitoGPS has identified a mechanism that can simultaneously induce a set of characteristics that define the advanced phenotypes of cancers, including: CR growth (8, 16, 56) , resistant to apoptosis (8), glycolytic flux (148, 308), in addition to, enhanced invasion and metastasis (8, 20, 56) . Mechanisms that have been identified for the mitoGPS are prospective (mitochondrial and nuclear encoded) markers for the selective penetrance, progression, and prognosis of PCa and BCa. Signaled by a metabolic-to-proto-oncogenic pathway, it is plausible that the mitoGPS is a ubiquitous (patho)physiological response to the etiology and/or progression of a broad spectrum of human diseases that are attributed to respiratory incompetent mitochondria, such as the clearly defined 'mtDNA depletion syndrome' and degenerative diseases (e.g., metabolic syndrome and diabetes) (57) (58) (59) (60) . Moreover, the identification of the complexity and the specificity of the mitoGPS could open the door for potential treatments to diseases that are associated with mitochondrial respiratory dysfunction, with therapies that are of restricted toxicity. The evidence obtained from the prostate cancer training award warrants further study the mechanics of the mitoGPS, as the outcome could enable a realistic fight against cancer, based on stalling and reversing the progression of the disease as we await the cure. It is important to note that C4-2 and LNρ0-8 were derived from the progression of LNCaP to an advanced disease, in vitro and in vivo, respectively. The denoted cell lines were transferred into a 96 well OxoPlate at the denoted concentrations. The O 2 concentration in the cell culture media was quantified with oxygen-sensors in the OxoPlate and a spectrophotometer for 2 hours of incubation. The data was reported as the mean ± SE (n = 3).
Fig. 5: The cellular expression of AR is diminished in response to the constitutive activation of ERK that develops from the depletion of the mitochondrial genome in PCa.
Depicted is a western blot of AR in 60 µg of total-protein lysates collected from ρ0 of LNCaP (LNρ0-8) that was cultured 48 hr in the absence or presence of PD98059 to inhibit the phosphorylation of ERK. Total-protein lysates were subjected to 8% SDS-PAGE, and subsequentially transferred onto membrane to be probed with anti-AR, anti-total-ERK, anti-phospho ERK to confirm the phosphorylation status of ERK, and anti-β-actin as a loading control. LNCaP were evaluated as a positive control for the AR and as a negative control for phospho-ERK.
Fig. 6: The cellular expression of AR is diminished in response to the constitutive activation of ERK that follows the depletion of the mitochondrial genome content from PCa (LNCaP).
Depicted is a western blot of AR in 60 µg of total-protein lysates collected from ρ0 of LNCaP (LNρ0-8) that was cultured 48 hr in the absence or presence of, either, GW5074 or U0126 to inhibit the phosphorylation of ERK. Total-protein lysates were subjected to 8% SDS-PAGE, and subsequentially transferred to membrane to be probed with anti-AR, anti-total-ERK, antiphospho ERK to confirm the phosphorylation status of ERK, and anti-β-actin as a loading control. LNCaP were evaluated as a positive control for the AR and as a negative control for phospho-ERK. Fig. 7 : The cellular transcription of AR is diminished in response to the constitutive activation of ERK that follows the depletion of the mitochondrial genome content from PCa (LNCaP). Depicted is the RT-PCR of the AR transcripts in 200 ng of total-cDNA constructed from total-RNA lysates collected from ρ0 of LNCaP (LNρ0-8) cultured 48 hr in the absence or presence of U0126, or PD98059, GW5074 to inhibit the phosphorylation of ERK. LNCaP was evaluated as a positive control for AR. It is important to note that the results are preliminary, due to the absence of re-expression of AR at high dose of PD98059 and GW5074. Repetition should include a proper loading control, such as GAPDH.
Fig. 8: LNCaP is sensitive to anti-androgen, flutamide.
Depicted is a graph of the viability of LNCaP that was seeded at a concentration of 2,000 cells/well in a 96 well plate, overnight. Cells were cultured 4 days in the absence (control) or presence of flutamide at the denoted dosages (n = 3). After treatment, the viability of cells was quantified in a calcein assay and the mean of each group was reported as a relative percent to the control (arbitrary unit ± SE). A student's t-test was conducted to compare samples to the control (*p < 0.05 and **p < 0.001). Error bars represent standard error.
Fig. 9: A flux in the mevalonate-to-Ras pathway, generated from the depletion of the mitochondrial genome content, in
PCa advances the disease to the AAR phenotype. Depicted is a graph of the viability of LNρ0-8 that was seeded at a concentration of 2,000 cells/well in a 96 well plate, overnight. Cells were cultured 4 days in the absence or presence of flutamide at the denoted dosage. Cells cultures were additionally supplemented without (control) or with 40 µM PD98059 (n = 3). After treatment, the viability of cells was quantified in a calcein assay and the mean of each group was reported as a relative percent to the control, 0 µg/mL Flutamide (arbitrary unit ± SE). A student's t-test was conducted to compare the viability of cells exposed to control and PD98059 conditions in the same dosage of flutamide (*p < 0.001). Error bars represent standard error. Changes in mitochondrial genome such as mutation, deletion and depletion are common in cancer and can determine advanced phenotype of cancer; however, detailed mechanisms have not been elucidated. We observed that loss of mitochondrial genome reversibly induced overexpression and activation of proto-oncogenic Ras, especially K-Ras 4A, responsible for the activation of AKT and ERK leading to advanced phenotype of prostate and breast cancer. Ras activation was induced by the overexpression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), the rate-limiting enzyme of the mevalonate pathway. Hypoxia is known to induce proteasomal degradation of HMGR. Well differentiated prostate and breast cancer cells with high mitochondrial DNA content consumed a large amount of oxygen and induced hypoxia. Loss of mitochondrial genome reduced oxygen consumption and increased in oxygen concentration in the cells. The hypoxic-to-normoxic shift led to the overexpression of HMGR through inhibiting proteasomal degradation. Therefore, reduction of mitochondrial genome content induced overexpression of HMGR through hypoxic to normoxic shift and subsequently the endogenous induction of the mevalonate pathway activated Ras that mediates advanced phenotype. Reduction of mitochondrial genome content was associated with the aggressive phenotype of prostate cancer in vitro cell line model and tissue specimens in vivo. Our results elucidate a coherent mechanism that directly links the mitochondrial genome with the advanced progression of the disease. Prostate cancer (PCa) is a significant health problem, representing the leading cancer diagnosis and the second leading cause of cancer death in North American men. 1 PCa begins as an androgen-dependent cancer that undergoes clinical regression in response to pharmacological or surgical strategies that reduce testosterone concentration. Despite this treatment, the cancer frequently recurs as an androgenindependent or castration-resistant cancer with metastatic phenotype. Therefore, elucidation of the mechanisms involved in the development to an aggressive metastatic phenotype is a critical topic. Mitochondria are essential organelles that generate ATP through oxidative phosphorylation. This process is accomplished by a series of protein complexes and mitochondrial respiratory chains encoded by nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Human mtDNA is remarkably small (16 569 bp) compared with nDNA (B10 9 bp) and encodes 13 proteins in the mitochondrial respiratory chains (MRC), 22 transfer RNAs, and 2 ribosomal RNAs. 2 Several reports showed that mutations of mtDNA had been identified in various types of cancer, including breast, colon, prostate, pancreatic and other cancers. 3 The growth advantage of cancer cells with specific mutant mtDNA has also been demonstrated in an in vivo mouse model system using cybrid (trans-mitochondrial hybrid) cells, suggesting that specific mutations of mtDNA give a survival advantage and induce metastasis. 4 In PCa specimens, Chen et al. 5 reported an extremely high incidence of somatic mutation (90%) in the D-loop region that may cause reduction of mtDNA content. 6 The roles of mtDNA and mitochondrial respiratory function in biological functions has been demonstrated using mtDNAdeficient cells. 7 We previously showed that TNF and serum starvation could not induce apoptosis in mtDNA-depleted cells, whereas they induced apoptosis in parental cells and cells reconstituted with normal mtDNA. 8 These results indicate that mitochondrial respiratory function and mtDNA are critically important in apoptosis. We showed following observations to demonstrate the mechanisms involved in the induction of advanced phenotype of PCa by the reduction of mitochondrial genome content. Reduction of mtDNA content shifted (1) androgen-dependent PCa cells to an androgenindependent phenotype in vitro and in vivo 9 and induced (2) epithelial-to-mesenchymal transition changes that may lead to PCa progression, 10 (3) hypermethylation of CpG islands of the putative tumor suppressor genes 11 and (4) abnormal activation of NF-kB, 12 AP-1, 12 AKT, 13 ERK 10 and JNK 10 that may lead to aggressive phenotype in PCa progression.
Consumption of oxygen: a mitochondrial-generated progression signal of advanced cancer
Ras-GTPases are potential candidates that can transduce the constitutive and concurrent activation of a broad array of effectors such as ERK and AKT. As small GTPases, Ras are dynamically activated and inactivated with the association of GTP or GDP, respectively. Human cancers (B25%) often harbor (oncogenic) mutations in Ras that disable the ability of the GTPases to dynamically be inactivated, leading to the constitutive and concurrent activation of a diverse array of signal pathways, for example, Raf/MEK/ERK and PI3K/Akt. 14 Although tissue studies have revealed the constitutive and concurrent activation of ERK and Akt in the progression of PCa, the majority of PCa tumors do not harbor RAS mutation (oncogenes). 15 Yet, it is generally acknowledged that the aberrant activation of Ras can shift PCa from androgen-dependent to independent, 16 whereas the expression of dominant-negative Ras attenuates androgen-independent phenotype, 17 indicating that Ras activation is responsible for the phenotype of PCa. In the current study of PCa, we investigated a pathway of metabolic and proto-oncogenic processes including Ras activation that aberrantly activates ERK and Akt. We denoted this as the mitochondrial-generated progression signal (mitoGPS) that transduces changes in mitochondrial genome in the early-stages of PCa into the advanced progression of the disease.
Results
Reduction of the mitochondrial genome content is associated with PCa progression. We first investigated whether mitochondrial genome content changes associated with aggressive phenotype of PCa in human tissue specimens. Mitochondrial genomic analysis in a single cell revealed that the mitochondrial genome copy-number/cell was significantly reduced in high-grade tumors (Gleason grade 8 and 9) as compared with that in low-grade tumors (Gleason grade 6 and 7) ( Figure 1a ) (Po0.01). The in vivo observations were verified in human cell lines the early stages androgen-dependent PCa (LNCaP), or an array of PCa (C4-2, PC-3 and DU-145). Classical cell lines for the in vitro evaluation of PCa, include: the castration sensitive LNCaP established from a metastatic (supraclavicular lymph node) lesion of human prostate adenocarcinoma; 18 the castration resistant (CR) C4-2 isolated from recurrent tumors that develop after castration of mice inoculated with LNCaP; 19 and CR PCa cell lines derived from metastasis in human bone (PC-3) and brain (DU-145). 20, 21 In the current study, mitochondrial genomic analysis showed a low mitochondrial genome content in PC-3 and DU-145, in addition to a significant reduction in C4-2, relative to the parental LNCaP (Figure 1b) .
Reduction of the mitochondrial genome content reversibly induces the aberrant activation of ERK and
Akt. We evaluated the biological impact of the reduction of the mitochondrial genome content in the progression of PCa by the experimental depletion of the genome from LNCaP. We additionally utilized the MCF-7 cell line, a classical breast cancer (BCa) established from the metastasis (pleural effusion) of a human breast adenocarcinoma. 22 The knock-out of the mtDNA (mtDNA-KO) from LNCaP and MCF-7 was demonstrated in the creation of the LNr0-8 and MCFr0 cell lines, respectively. 9, 10 To confirm that experimental observations that follow the loss of the mitochondrial genome content are not of consequence to an incidental mutation to the nuclear genome induced by ethidium bromide treatment, the mitochondrial genome was reconstituted to the mtDNA-KO cell lines (LNr0-8 and MCFr0) in the creation of the mtDNA-knock in (mtDNA-KI) cells lines, denoted as LNCyb and MCFCyb.
The mitochondrial genome contents of the indicated cell lines were visually confirmed by fluorescent in situ hybridization (FISH). Mitochondria were labeled with MitoTracker Red and showed that presence of mitochondria in parental, mtDNA-KO and mtDNA-KI cells (Figure 1c ). Microscopic (confocal) images also show the abundance of the mtDNA probes localized in the mitochondria of the parental and mtDNA-KI cells; no mtDNA probes were observed in the mtDNA-KO cells (Figure 1c) . The results were confirmed by the quantification of the mitochondrial genome content by QRT-PCR (Figure 1d) ; the mitochondrial genome content in LNCyb and MCFCyb was partially or completely restored, respectively, to that in LNCaP and MCF-7. We observed that the amount of ATP in LNCaP was significantly reduced in LNr0-8 (113.3±2.0 and 73.2±2.1 nM/mg protein, respectively) (average ± S.E., P-value ¼ 0.0056) and lactate generation was increased (1463±66 and 3416± 82 nM, respectively) (average±S.E., P-value ¼ 0.000049). The results suggest that loss of mitochondrial genome reduced ATP generation possibly by the reduction of oxidative phosphorylation that might increase in anaerobic glycolysis.
It is well documented that ERK and Akt are constitutively activated in the progression of advanced PCa tumors. 15 Our data reveal ERK and Akt to be constitutively activated in the mtDNA-KO of PCa and BCa, relative to the parental and mtDNA-KI cells (Figure 1e ). Of the ERKs, that is, ERK1 (p44) and ERK2 (p42), ERK2 was the most dramatically phosphorylated in LNr0-8 and MCFr0.
Reduction of the mitochondrial genome content in PCa and BCa constitutively activates Ras. The interaction of activated GTP-bound Ras with the Ras binding domain (RBD) of Raf-1, 23 generates GTP-bound Ras-Raf complexes that lead to the activation of ERK and Akt. 24, 25 We investigated whether Ras is activated by depletion of mitochondrial genome. No active Ras was pulled-down from the total-protein lysates (160 mg) of parental (LNCaP and MCF-7) cells in comparison with a positive control (Figure 2a ). Meanwhile, active Ras from mtDNA-KO was observed even when the quantity of LNr0-8 and MCFr0 lysates probed was reduced to 0.5 mg or 5 mg, respectively, active Ras was observed as two bands of intensity similar to the positive control (Figure 2a ). The experiment demonstrates that the depletion of the mitochondrial genome in PCa leads to the constitutive activation of Ras. Association of the reduction of mitochondrial genome content with the activation of Ras was verified in an array of PCa C4-2, PC-3 and DU-145 that harbor low mitochondrial (Figures 1b and 2b) . The shift of normal epithelial cells to the early-stages of PCa and BCa is associated with the genetic silencing of RasGAPs, particularly the DOC-2/DAB2 interactive protein (DAB2IP). 26 The attenuation of DAB2IP activity in PCa diminishes the cells ability to amplify the GTPase activity of Ras, leading to the prolonged accumulation of active GTP-bound Ras. 27 We observed the expression of DAB2IP to be expressed in the prostate epithelial cells (PrEC), but not in all PCa including LNCaP, C4-2, DU-145 and PC-3 (Figure 2c ). Collectively the experiments demonstrate that the shift of normal prostate epithelial cells to PCa is associated with a silencing of a RasGAP that is not enough to explain why Ras is not activated in early stages of PCa LNCaP.
Reduction of the mitochondrial genome content in PCa overexpresses proto-oncogenic K-Ras 4A. The human cell contains three nuclear-encoded RAS genes that encode four isoforms of Ras: H-Ras, N-Ras and two splice variations of K-Ras, K-Ras 4A and K-Ras 4B. We observed the protein level of K-Ras 4A to be greatly elevated in the mtDNA-KO (LNr0-8 and MCFr0), relative to the parental cells. Reconstitution of the mitochondrial genome to the mtDNA-KO attenuated the aberrant K-Ras 4A expression ( Figure 3a ). Expression level of K-Ras 4A in mtDNA-KO cells was exceptionally high as compared with that of K-Ras 4B, H-Ras and N-Ras. A similar expression pattern was observed for the transcript levels of K-Ras 4A (Figure 3b ). Association of the reduction of mitochondrial genome content with increased expression of K-Ras 4A was verified in an array of PCa C4-2, PC-3 and DU-145 that harbor low mitochondrial genome contents, relative to the early stages of PCa LNCaP (Figures 1b and 3c) .
We note that the constitutive activation of Ras observed with the depletion of the mitochondrial genome was not a consequence of oncogenic mutation in nucleotide sequences that encode for codons 12, 13 or 61 of K-Ras. 28 In a subsequent experiment we demonstrated that silencing of K-RAS in LNr0-8, by transfection of K-RAS siRNA, reduced the expression of K-Ras 4A and the phosphorylation of ERK and Akt, but not total ERK nor total AKT (Figure 3d ). Collectively, the experiments demonstrate that the reduction of the mitochondrial genome leads to the aberrant expression and activation of Ras, predominantly proto-oncogenic K-Ras 4A, and a process that is reversible with the reconstitution of the mitochondrial genome. expression is responsible for the aberrant activation of Ras mediated by the reduction of the mitochondrial genome content. Ras must translocate to cellular membrane by post-translational modifications that enable the (GTP-bound) Ras-Raf complexes to activate effectors at cellular membranes. 29 Localization of Ras to the cellular membrane is mediated by the prenylation of Ras, that is, the addition of farnesyl to the first cysteine (CAAX) of the C-terminus. 30 Farnesyl moieties for the prenylation of Ras are derived from farnesyl pyrophosphate, an intermediate of the mevalonate pathway that is catalytically transferred by farnesyltransferase (FTase). 31 Immunohistochemical analysis confirmed that expression of Ras was greatly increased in LNr0-8 as compared with LNCaP (Figure 4a ). Figures 4a and b also demonstrates that Ras located only in cytosolic fraction in LNCaP and cellular membrane and certain organelle in LNr0-8
suggesting that the depletion of the mitochondrial genome signals the localization of Ras to the cellular membrane and specific organelle. Farnesylation of Ras can be repressed with lovastatin-mediated inhibition of the ratelimiting step of the mevalonate pathway -the metabolism of HMG-CoA to mevalonate by HMGR. 32 Addition of lovastatin to the culture of LNr0-8 generated the cytosolic accumulation of Ras, in addition to a shift to LNCaP-like cell morphology, both of which were reversed with co-application of exogenous mevalonate (Figure 4b ). To directly inhibit the farnesylation of Ras, farnesyltransferase inhibitors (FTIs) have been designed as peptidomimetics of the C-terminus (CAAX) of Ras. 32 The supplementation of lovastatin or FTI-276 diminished the phosphorylation of ERK and Akt in LNr0-8 (Figures 4c and d) . The results suggest that the endogenous activity of the mevalonate pathway is necessary for the constitutive activation of Ras in LNr0-8. Then, we further investigated the potential cause for upregulation of mevalonate pathway. We observed an elevation of the expression of HMGR with the depletion of the mitochondrial genome (LNr0-8) could be attenuated with the reconstitution of the genome (LNCyb) (Figure 4e ). We also observed the expression of HMGR was enhanced associated with the reduction of the mitochondrial genome content in PCa cell lines (Figure 4f ). These results indicate that an elevation in the endogenous expression of HMGR is responsible for the activation of Ras when the mitochondrial genome content is reduced.
Inhibition of mitochondrial respiration is responsible for HMGR expression possibly through the inhibition of proteasomal degradation. Mitochondrial genome encodes 13 proteins in MRC and therefore reduction of mitochondrial genome leads to the inhibition of mitochondrial respiration.
To determine if the induction of HMGR expression is induced by the inhibition of mitochondrial respiration, LNCaP cells were cultured in the absence or presence of inhibitors of various complexes of the MRC: rotenone inhibits complex I; antimycin A inhibits complex III; oligomycin inhibits Fo-ATPase of complex V. Rotenone, antimycin A and oligomycin at the concentration used inhibited the oxygen consumption rate of LNCaP (32.6%, 35.2% and 34.4%, respectively) and enhanced the expression of HMGR (Figure 5a ).
HMGR is regulated by multiple feedback mechanisms, including: transcriptional and/or translational regulation, PTMs, and/or proteasomal degradation by both sterol and non-sterol products of the mevalonate pathway. 33 We investigated whether proteasomal degradation is associated with high expression of HMGR. Incubation with proteasomal inhibitor N-[N-(N-Acetyl-L-leucyl)-L-leucyl]-L-norleucine (ALLN) in LNCaP increased the protein level of HMGR (Figure 5b ), suggesting that early stage PCa maintain low expression level of HMGR by proteasomal degradation.
HMGR expression in PCa is enhanced by the hypoxicto-normoxic shift. A recent study has demonstrated that hypoxia induces the proteasomal degradation of HMGR. 34, 35 As expected, oxygen consumption is well associated with the content of mitochondrial genome in PCa cell lines ( Figures  1b and 6a ). From this observation, we hypothesized that LNCaP cells induce hypoxia by high consumption rate of oxygen leading to hypoxia-induced HMGR degradation, and that in advanced PCa the hypoxic state is retarded with the inhibition of respiration, that is, by the reduction of mitochondrial genome content, leading to the accumulation of HMGR expression. Interestingly, the oxygen concentration of surrounding cells was greatly reduced with the culture of LNCaP and MCF-7, as observed with the induction of hypoxia (12.3 and 4.2 mM, respectively) in an hour ( Figures  6b and c, respectively) . The hypoxia-inducing activity of the parental cells was greatly reduced with the depletion of the mitochondrial genome, and recovered with the reconstitution of the genome (Figures 6b and c) . To investigate whether the hypoxic-to-normoxic shift induced by the reduction of mitochondrial genome content augments the expression of HMGR, the oxygen condition in the culture of LNCaP cells was increased (30%, 310 mM) to establish an increased intracellular oxygen condition. The expression of HMGR and the phosphorylation of ERK were amplified within 6 h of culture in the enriched oxygen condition (Figure 6d ). The study was further refined by the culture of LNr0-8 in low oxygen environments to exogenously induce a normoxic-tohypoxic shift in LNr0-8. The greatly reduced-oxygen condition (0.2%, 2.1 mM), but not 1, 5 or 20%, attenuated the expression of HMGR and the phosphorylation of ERK (Figure 6e ), within 6 h of culture in the 0.2% oxygen environments (Figure 6f ). The data indicate that hypoxic-tonormoxic or normoxic-to-hypoxic shifts regulate the protein levels of the HMGR enzyme. We observed the hypoxiainducing activity of advanced PCa cell lines to be low (Figure 6g ), an observation that correlates with the oxygen consumption ( Figure 6a ) and the dysregulation/reduction of the steady state of the mitochondrial genome content in the progression of PCa (Figure 1b) .
Endogenous or exogenous induction of the mevalonate pathway in PCa signals the progression of the advanced phenotype in vitro and in vivo. To verify that exogenous androgens amplify the viability of the early-stages PCa, LNCaP were cultured in androgen-deprived media without ( Figure 7a ) or with synthetic androgen (R1881) (Figure 7b) . Meanwhile, the androgen-deprived media was supplemented with exogenous mevalonate to induce the mevalonate pathway in the absence or presence of exogenous androgen (Figures 7c and d, respectively) . Figure 7e demonstrates that exogenous androgens amplify the growth and proliferation of LNCaP in a dose-dependent fashion that is diminished in the presence of exogenous mevalonate. Alternatively, mevalonate alone supports growth in the absence of exogenous androgen (Figures 7c and e ). The experiment reveals that exogenous mevalonate induces androgen independence.
In subsequent experiments we evaluated the essentialness of the endogenous mevalonate pathway on the viability of (Figure 7f) ; the lovastatin-mediated inhibition of the viability of the mtDNA-KO was prevented by mevalonate ( Figure 7g ). The experiments demonstrate that a reduction of the mitochondrial genome content in PCa is transduced into the advanced phenotype via an endogenous induction of the mevalonate pathway. LNCaP cells are known to gradually acquire more aggressive growth within in vitro and in vivo environments. 36, 37 In order to investigate, in vivo, the role of mevalonate pathway in the shift of LNCaP to more aggressive growth phenotype, we inoculated LNCaP cells into athymic nude mice. Following the development of tumors with diameters of 9-10 mm, mice were randomly assigned to four experimental groups as follows;
(1) control, (2) lovastatin, (3) mevalonate and (4) lovastatin and mevalonate. The mean tumor volume for each group was quantified on Day 0 (pre-treatment): 377 ± 105, 336 ± 106, 454±86 and 383±44 (average±S.D. mm 3 ). Subsequently, pumps were utilized to systemically deliver either mevalonate (group 3 and group 4) or isotonic saline (group 1 and group 2) into mice, whereas lovastatin was consumed in the diet of mice of group 2 and group 4. Figure 8a demonstrates that the progressive growth of LNCaP (group 1) in mice was significantly reduced with the treatment of lovastatin (group 2); the growth inhibitory effect of lovastatin was reversed with exogenous mevalonate (group 4). Meanwhile, the administration of exogenous mevalonate alone (group 3) slightly but significantly enhanced the growth of LNCaP. These results indicate that the mevalonate pathway is responsible for in vivo advanced growth in the xerographic model of PCa.
Discussion
Our collective report demonstrates in PCa that the (1) inhibition of respiration, by reduction of the mitochondrial genome content, shifts cells from a hypoxic-to-normoxic state (2) that attenuates the endogenous proteasomal degradation of the HMGR enzyme; (3) the increase in mevalonate pathway (4) induces the constitutive activation of nuclear-encoded proto-oncogenic Ras (5) that signal for an array of cancer progression signals (Figure 8b) . We denote the coherent series of events as the mitoGPS. The pathological condition of a deprivation in an adequate oxygen supply to the body is referred to as hypoxia, a condition that is transduced at the molecular level into hypoxia-related signals that allow a cell(s) to adjust to the extracellular environment. We are the first to directly establish the mitochondrion as a direct physiological source of hypoxia in an in vitro system. Our results demonstrate that the reduction of the mitochondrial genome content diminishes the hypoxic state of the early stages of PCa and BCa, generating a hypoxic-to-hyperoxic shift in the oxygen content that is transduced into the overexpression of HMGR; subsequently, the induction of the mevalonate pathway activates proto-oncogenic Ras that signals the constitutive and concurrent activation of a diverse array of cancer progression Figure 8 The effect of lovastatin and mevalonate on tumor formations of LNCaP in athymic nude mice. Athymic BALB/c (nu/nu) mice were subcutaneously inoculated with LNCaP. The effect of lovastatin and mevalonate on tumor growth was investigated as described in Materials and Methods. The tumor volumes were measured weekly and calculated. The relative tumor volume was calculated as percent of control ± S.D. by assuming the rate of each tumor volume on day 0 to be 100% (n ¼ 6). Student's t-test compared the control and lovastatin group showed significance at day 14, 21 and 28 days (*Po0.01), and the control and mevalonate groups at day 14 and 21 (**Po0.01) and 28 days (***Po0.02) Prostate cancer progression and mitochondrial DNA CC Cook et al pathways that advance the disease. Reports indicate that hypoxia inhibits lanosterol demethylase, an oxygen requiring enzyme, and accumulates lanosterol (molecules in cholesterol pathway) and that accumulation of lanosterol induces Insigmediated degradation of HMGR. Hypoxia also activates HIF-1 to induce expression of insig. 34, 35 Whether this pathway is activated in our system is now under investigation. The roles of ROS may not be likely as mtDNA-deficient cells generate reduced superoxide. 38 With primary PCa composed of a mixture of cells with high or low mitochondrial genome content, 39 cells with high mitochondrial content may generate more hypoxia-induced changes that benefit the growth and maintenance of both groups under high cell density conditions, that is, the primary tumor site. In contrast, we speculate in the initiation of metastasis that the progressive induction of hyperoxia with the reduction of cell-density further enhances the mitoGPS, advancing the phenotype of cancer that harbor a reduced copy-number of the mitochondrial genome. It is plausible that the mitoGPS is a ubiquitous (patho)physiological response to the etiology and/or progression of a broad spectrum of human diseases that are attributed to respiratory incompetent mitochondria in various degenerative diseases (e.g., metabolic syndrome and diabetes). For example, as K-Ras 4A is responsible for aldosterone signaling, 40 the roles of mtDNA changes on hypertension is implicated.
In conclusion, our report has identified an intricate interaction of prospective (mitochondrial and nuclear encoded) markers for the selective penetrance, progression and prognosis of PCa, and potentially a diverse array of respiratorydeficient (e.g., aging) pathologies.
Oxygen concentration measurements by OxoPlate. The OxoPlate OP96U (PreSens) contains oxygen-sensitive, polystyrene particles PSLi-Pt-1 (Opto-Sense). Sulforhodamin is covalently attached to these particles as reference dye, and a platinum porphin is incorporated as indicator dye. The sensor has a thickness of about 10 mm and is fixed at the bottom of each well of a 96-round bottom microtiter plate (Greiner, Monroe, NC, USA). Cells (200 ml) were added to each well at the indicated cell density. Wells containing oxygen-free water (cal 0) and air-saturated water (cal 100) served as standards. Oxygen-free water was prepared by dissolving sodium sulfite (1%) in water; in the wells, the oxygen-free water was overlaid with mineral oil (50 ml) to prevent the diffusion of oxygen into the wells. The oxygen concentration (fluorescence) in each well was quantified for 3 h in 5-min intervals, as measured in a dual kinetic mode (Synergy HT, BIO-TEK, Einooski, VT, USA): filter pair 1 (544/650 nm) detects fluorescence of the indicator dye; the second measures fluorescence (544/590 nm) of the reference dye (n ¼ 3).
Calculation of oxygen concentration. The relationship between fluorescence and dissolved oxygen is nonlinear, as described by the Stern-Volmer equation:
where, I R,0 is the fluorescence intensity ratio in the absence of oxygen; I R is the fluorescence intensity ratio at the oxygen concentration [O 2 ], and K SV the Oxygen concentration as a percentage of air saturation was calculated for each well, as follows:
where the constant K 0 is defined as I R of well filled with cal 0. Analogously, K 100 is defined as I R of well filled with cal 100.
